Women’s rights, Plan C access under attack in FDA court cases

By Roxy Nightshade

Since Roe vs Wade was overturned in 2022, the attack on a woman’s right over her own body continues to intensify in conservative states. Next on the chopping block is mifepristone, one of the two drugs in the abortion pill, Plan C. A court case in Louisiana — Louisiana v. FDA — is currently seeking to eliminate mifepristone prescription by TeleHealth and shipping by mail.

Medication abortion — a two drug combination of mifepristone and misoprostol — is the most common form in the USA accounting for greater than 60 percent of abortions each year. It is approved by the FDA for up to 10 weeks of pregnancy, but has been shown to work up to 12 weeks, and is approved by the World Health Organization for up to 12 weeks. 

Decades of scientific evidence prove mifepristone to be a safe and effective pharmaceutical procedure, and 7.5 million pregnant people in the USA have utilized it since it was approved in 2000. It is effective at ending pregnancy greater than 95 percent of the time, and studies show that 99 percent of patients have no serious side effects.

Telehealth prescription is a lifeline for patients in a multitude of situations — those who live far away from clinics in rural and medically underserved areas, women who can’t leave work or caregiving to travel to a clinic, women with disabilities, and women in states with bans who obtain care from doctors in states with shield laws 

A quarter of all abortions — which is a twofold increase since Roe vs Wade was overturned — are now provided via Telehealth. 

In 2023, the FDA performed a Risk Evaluation and Mitigation Stategy (REMS) of mifepristone, and this removed the in-person dispensing requirement and permitted certified pharmacies to dispense mifepristone, including by mail. Research shows mifepristone to be prescribed just as safely via Telehealth as in person with a provider.

Louisiana v. FDA is one of several court cases, along with those in Texas, Florida and Missouri, brought by abortion ban states that are attempting to restrict access to mifepristone in the US. This case was filed by the anti-rights group Alliance Defending Freedom on behalf of the state of Louisiana and an individual woman, against the Food and Drug Administration (FDA) in October 2025. 

Louisiana seeks to restrict abortion pill access by eliminating Telehealth and delivery by mail and reinstating the in-person dispensing requirement with a provider, which is medically unnecessary. This would end mail distribution and would also stop pharmacies from filling mifepristone prescriptions for all patients, including those using it to manage a miscarriage.  

The Texas, Florida and Missouri cases could go even further, by calling for the withdrawal of mifepristone altogether, or by finding that the Comstock Act prohibits the mailing of all abortion pills. 

The Comstock Act is a series of federal laws passed in 1873 that prohibits the use of mail to transport medications and obstetrical supplies intended for use in unlawful abortion care. It was a “zombie law,” meaning it remained on the books but was not enforced. 

In December 2022, after Roe v. Wade was overturned, the Department of Justice released a legal memo making clear that the Comstock Act does not prohibit mailing of medication abortion, unless the sender intends the drugs to be used unlawfully.  But now, anti-rights activists are attempting to revive the Comstock Act to indicate otherwise.

Currently, the Trump administration is conducting its own politically motivated “review” of the safety of mifepristone. 

In January 2026, the FDA asked the court to hold the case until the administration is finished with the review. The request was granted in April, thus pausing the case. The Supreme Court has allowed continued access to mifepristone via mail and at pharmacies as the case is paused. 

The FDA was required to file a status report on its review of the REMS for mifepristone on Oct. 7. The status report’s timeline puts the FDA’s study results after the Nov. 3 election, with the FDA expecting results by mid-December and a written report no later than March.

The FDA must refuse political pressure to restrict mifepristone access, and continue to abide by evidence-based research and what is best for patients. The courts and politicians should not invoke antiquated laws like the Comstock Act as the grounds to restrict this safe and effective abortion method.  

National Women’s Liberation in Gainesville is urging folks to advocate and either call or e-mail the FDA and urge them to keep Telehealth access to providers for mifepristone prescription and to allow prescription delivery by mail. Call: 855-543-3784 — FDA’s Center for Drug Evaluation and Research (CDER). Email: druginfo@fda.hhs.gov. 

For information on Plan C and how to access it in Florida, visit plancpills.org.

Comments are closed.